Regentis Biomaterials Ltd. (RGNT) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Regentis Biomaterials Ltd. (RGNT) stock forecast summary
Our AI scores Regentis Biomaterials Ltd. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Regentis Biomaterials Ltd. is a small-cap company with a market capitalization of $8M. It ranks number 22 by market capitalization among the 26 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.
For RGNT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 55.0%, measured on 119 forecast dates between 2026-02-24 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 62.0%, measured on 162 forecast dates between 2026-02-24 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RGNT included.
RGNT price chart and AI forecast
How RGNT ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Regentis Biomaterials Ltd. (RGNT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | RGNT | Rank |
|---|---|---|
| Market Cap | $8M | 22/26 |
| P/B Ratio | 1.73x | 12/20 |
| Book Value/Share | $0.68 | – |
Financial Health
| Metric | RGNT | Rank |
|---|---|---|
| D/E Ratio | 0.61x | 15/23 |
| Financial Leverage | 1.61x | 15/23 |
| Interest Coverage | -88.2x | 13/20 |
Dividend & Shareholder Information
| Metric | RGNT | Rank |
|---|---|---|
| Shares Outstanding | 7M | – |
Balance Sheet Highlights (USD millions)
| Cash & Short-term Investments | $7M | 96.8% of assets |
| Total Liabilities | $3M | 37.7% of assets |
RGNT quarterly financials and insider trading
Regentis Biomaterials Ltd. (RGNT) industry peers
Companies classified under the same SEC industry code as Regentis Biomaterials Ltd. (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 26 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RGNT Regentis Biomaterials Ltd. | $8M | |
| ISRG Intuitive Surgical Inc | $156.96B | |
| STE Steris Plc | $24.60B | |
| ZBH Zimmer Biomet Holdings, Inc. | $20.38B | |
| SNN Smith & Nephew Plc | $13.67B | |
| ALGN Align Technology Inc | $11.79B | |
| MSA Msa Safety Inc | $6.56B | |
| ESTA Establishment Labs Holdings Inc. | $1.92B | |
| ENOV Enovis Corp | $1.57B | |
| CDRE Cadre Holdings, Inc. | $1.40B | |
| AVR Anteris Technologies Global Corp. | $555M | |
| SMTI Sanara Medtech Inc. | $290M | |
| INGN Inogen Inc | $160M | |
| LAKE Lakeland Industries Inc | $89M | |
| NTRB Nutriband Inc. | $68M | |
| APT Alpha Pro Tech Ltd | $56M | |
| COCH Envoy Medical, Inc. | $55M | |
| MYO Myomo, Inc. | $48M | |
| MLSS Milestone Scientific Inc. | $27M | |
| LFWD Lifeward Ltd. | $16M | |
| CUPR Cuprina Holdings (Cayman) Ltd | $12M | |
| UEEC United Health Products, Inc. | $10M | |
| CLGN Collplant Biotechnologies Ltd | $7M | |
| BBLG Bone Biologics Corp | $1M | |
| FEED Envue Medical, Inc. | $240K | |
| RBOT Vicarious Surgical Inc. | $10K |
Where RGNT sits on the market map
Regentis Biomaterials Ltd. (RGNT) stock news
Loading...
Regentis Biomaterials Ltd. (RGNT) stock forecast FAQ
What is the Regentis Biomaterials Ltd. (RGNT) stock forecast?
Our AI scores Regentis Biomaterials Ltd. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Regentis Biomaterials Ltd. stock predictions?
For RGNT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 55.0%, measured on 119 forecast dates between 2026-02-24 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 62.0%, measured on 162 forecast dates between 2026-02-24 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Regentis Biomaterials Ltd. forecasts updated?
Regentis Biomaterials Ltd. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Regentis Biomaterials Ltd.'s industry peers?
26 issuers in our coverage, RGNT included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.